Bacampicillin, a new oral prodrug which in vivo is rapidly transformed to ampicillin, was compared with ampicillin, pivampicillin, and amoxycillin in a randomized cross-over study on 11 healthy volunteers. All drugs were given in oral doses equimolar to 400 mg of bacampicillin (800 ,umol). The mean of the individual peak concentrations in serum was 8.3 jig/ml for bacampicillin, 7.1 ,ug/ml for pivampicillin, 7.7 ,ug/ml for amoxycillin, and 3.7 ,ug/ml for ampicillin. Furthermore, bacampicillin had a higher absorption rate than all the other drugs, although there were statistically significant differences only versus ampicillin. The peak serum levels of the individual subjects were more dispersed with ampicillin and amoxycillin, suggesting a more uniform absorption of bacampicillin and pivampicillin. The relative bioavailability of bacampicillin and pivampicillin was comparable, whereas ampicillin was only 2/3 that of the others.
others.
Ampicillin combines a low toxicity and broad antibacterial spectrum, but one disadvantage is its incomplete absorption. Small modifications of the molecule such as the insertion of a hydroxy group on the benzene ring in amoxycillin have improved absorption without essentially altering the antibiotic spectrum (27) , although less activity in vitro against some species (3, 21, 32) and clinical inferiority (20) against Shigella have been noted in comparison with ampicillin. An improvement has been achieved by esterification of the carboxyl group with radicals which leads to increased lipid solubility and improved absorption. Upon uptake, the radicals are rapidly detached by hydrolysis, and free ampicillin is made available in blood and tissues. Examples of this class of compounds are pivampicillin (28, 29) and talampicillin (5, 25) .
A systematic search for a new ampicillin ester combining good bioavailability with virtual lack of gastrointestinal distress and diarrhea has led to bacampicillin [1'-ethoxycarbonyloxyethyl-6-(n-a-aminophenylacetamido)-penicillinate]. This is rapidly absorbed and transformed to ampicillin with a concomitant rapid breakdown of the ethoxycarbonyloxyethyl ester group to acetaldehyde, ethanol, and carbon dioxide. The hydrolysis proceeds so rapidly that no systemic bacampicillin has been detected (4) . In animals, the new antibiotic is better absorbed than amp-iilin, giving higher and earlier peak blood,7evels of ampicillin (4, 9a) .
Studies with bacampicillin in healthy volunteers gave peak serum levels approximately 2.5 times higher than those after an equimolar dose of ampicillin. Mean individual peak serum levels after administration of 200, 400, and 800 mg of bacampicillin were 5.3, 8.9, and 16.5 ,ug/ ml, respectively (18) . Bacampicillin has rendered bioavailabilities of 87 to 95% (26; T. Bergan, submitted for publication).
With the various modifications of ampicillin and ampicillin-like antibiotics presently at the research stage, careful pharmacokinetic evaluations in controlled cross-over studies are important to reveal the points of distinction between them. The purpose of the present study was to compare the pharmacokinetics ofbacampicillin, ampicillin, pivampicillin, and amoxycillin. nase, serum glutamic pyruvic transaminase, and thymol) and kidney (blood urea nitrogen and serum creatinine) as well as hemoglobin and erythrocyte sedimentation rate were within the normal ranges. All subjects were informed of the nature of the study, possible side effects, and the potential role of ampicillin and amoxycillin as allergens. They were insured against mishaps during the study.
MATERIALS AND METHODS

Subjects
Pharmaceutical preparations. Bacampicillin, synthesized at the Research and Development Laboratories, Astra Lakemedel AB, was used as the hydrochloride. Bacampicillin was administered as 400-mg tablets (batch no. 141 A), ampicillin as 278-mg tablets (batch no. 740329), pivampicillin as 398-mg capsules (batch no. 741010), and amoxycillin as 291-mg tablets (batch no. 30). Pivampicillin substance was obtained from a commercially available capsule preparation, Pondocillin, from Lovens Kemiske Fabrik, Denmark, and amoxycillin from Beecham Pharmaceuticals, England; bacampicillin and ampicillin trihydrate were manufactured by Astra Lakemedel AB, Sweden. All formulations were prepared by Astra Lakemedel AB.
Iodometric analysis of the actual contents per dosage unit showed only insignificant deviation from intended amounts. The difference was less than 1% for bacampicillin and ampicillin, 1.5% for pivampicillin, and 2% for amoxycillin.
Dosage. The drugs were given in single equimolar (800 Amol) doses: bacampicillin, 400 mg; ampicillin, 278 mg; pivampicillin, 398 mg; and amoxycillin, 291 mg. The doses were taken under supervision with 100 ml of water. Experimental design. The study was carried out in a complete cross-over fashion, i.e., all subjects receiving all four preparations. Each subject received the drugs in a randomized order, implying that different preparations were given to the subjects on the same day. One week elapsed between doses. No food was allowed from midnight before until 2 h after swallowing the tablets. Intake of water was permitted ad libitum except during the last hour before and the first after medication. The volunteers were instructed not to take any other drug during the period of study.
Sampling. Samples (12 (1) c(t) being serum concentration at time t, k, the first order absorption rate constant, k2 the overall first order elimination rate constant, and c0 the fictive serum concentration at time t = 0. The validity of this assumption was tested by plotting against time:
When the one-compartment open model applies, the resulting curves should level off asymptotically with time.
Amoxycillin (7, 8) , bacampicillin (11, 18) , and pivampicillin (16) have previously shown a linear relationship between dose and area under the serum concentration-time curve. Assuming that the same proportion of each dose is absorbed, this indicates dose-independent kinetics, which is a prerequisite for the applicability of the first order, one-compartment open model.
For each subject, the constants (kl, k2, c0) of the time-concentration curves were estimated using an iterative, nonlinear regression analysis technique (BMD 07R) (9).
The serum half-life, tl/2, was calculated from k2:
The apparent absorption lag time, i.e., the time from drug administration until absorption started, was estimated graphically (22) .
The area under the serum concentration-time curve (AUC) was calculated by the trapezoidal rule based on measured values, and the estimated area from the last sampling time to infinity was calculated by:
AUC -c(t) k2 (4) An estimation of the relative bioavailability was made by comparing the average areas under the serum concentration-time curves after bacampicillin with those of ampicillin and pivampicillin. Since amoxycillin is active as such and no, converted to ampicillin, the area under the serum concentrationtime curve cannot be used in a bioavailability comparison to the ampicillin drugs. Statistical evaluation. Concerning the estimation of the pharmacokinetic constants, it is a well-known fact (31) that the results from models involving linear combinations of exponentials are numerically unstable. This is especially so, for example, in equation (1) when the true values of k, and k2 are close together, as is frequently seen with drugs that have a short half-life like the penicillins.
We have experienced this problem for some of the estimated curves. However, comprehensive computer experimentation has convinced us that the relationship between drugs regarding the estimated parameters is very little influenced by this instability. This justifies the inclusion of all estimated curves in the material although some of these produce unsatisfactory estimates of the individual parameters.
Since the true underlying distribution of some of the studied variables is typically non-normal, the nonparametric Friedman analysis of variance was uniformly applied in the statistical analysis. In the first stage, the overall hypothesis of equal location of a variable for the compared drugs was tested. If this hypothesis was rejected, the analysis was followed up with a multiple-comparison procedure based on the Friedman rank sums, where all pairwise comparisons were performed (12) . 
RESULTS
Serum concentrations. In Fig. 1 are shown the serum concentrations of each individual volunteer. Pre-administration samples showed no antibiotic activity. The peak serum levels were above 5 ,ug/ml in all subjects after bacampicillin and in all but one after pivampicillin, whereas, after amoxycillin and ampicillin, three and eight subjects, respectively, were below this level. Figure 2 shows the mean serum concentration curves for each antibiotic. Amoxycillin being active as such and not as ampicillin, the amoxycillin curve has been drawn in an equimolar scale with ampicillin, and the right hand ordinate indicates the actual amoxycillin concentrations. The mean curve for bacampicillin showed a tendency to both an earlier and a higher peak than the others. The means of the individual peak levels (Table 1) of bacampicillin (8.27 ,ug/ml), pivampicillin (7.14 ,ag/ml), and amoxycillin (7.68 deviation (SD) and coefficients of variation (CV) of the individual peak serum concentrations after equimolar 800 ,umol) oral doses of bacampicillin (400 mg), ampicillin (278 mg), pivampicillin (398 mg), and amoxycillin (291 mg). ml) on the one hand and that of ampicillin (3.70 ,ug/ml) on the other were significantly different (P < 0.001, P < 0.01, P < 0.05, respectively).
The mean area under the serum concentra- Table 1 shows the variation of the individual peak concentrations expressed by the coefficient of variation, i.e., the ratio between the standard deviation and mean concentration. Generally, the higher the concentrations, the more individual variation is to be expected. Thus, the smaller coefficients of variation seen after the ampicillin esters are notable. Since there is no established method for making statistical comparisons of coefficients of variation, the conclusions in this case are essentially of a descriptive nature.
Absorption. The median apparent absorption lag time was 0 h with bacampicillin and amoxycillin, compared with 0.2 and 0.35 h with pivampicillin and ampicillin. The ranges of the individual values, in hours, were 0 to 0.25 with bacampicillin, 0.12 to 0.80 with ampicillin, 0 to 0.40 with pivampicillin, and 0 to 0.55 with amoxycillin. The shorter range for bacampicillin is also reflected by the higher peak serum level after bacampicillin (Fig. 2) . The lag time for bacampicillin was significantly shorter than that for ampicillin (P < 0.01).
The rate constants of absorption, k, were highest for bacampicillin ( Table 2 ). The mean difference of k, between bacampicillin and ampicillin was statistically significant at P < 0.01, and between bacampicillin and amoxycillin atP < 0.05.
Elimination. There were small differences in the elimination rates (h-1) of the four compounds (Table 2) , the mean values ranging from 1.00 for bacampicillin to 0.66 for ampicillin, corresponding to serum half-life values of 0.75 to 1.09 h.
Renal elimination. The percentage of urinary recovery of the antibiotics in active form is shown in Fig. 3 . During the 8-h collection period, 71.5 + 10.5% (mean + standard deviation) of the ampicillin in bacampicillin was recovered. The corresponding figures for pivampicillin, ampicillin, and amoxycillin were 64.7 ± 19.1, 44.6 + 14.8, and 73.5 + 9.4%, respectively. The difference between excretion after bacampicillin and after ampicillin was statistically significant (P < 0.01), as was that between the latter and amoxycillin (P < 0.05).
Bioavailability. The relative bioavailability compared with bacampicillin was 0.67 for ampicillin and 0.98 for pivampicillin. Compared with bacampicillin, the relative urinary recovery of active ampicillin was 0.62 for ampicillin and 0.91 for pivampicillin. 
DISCUSSION
The mean serum concentration curves (Fig.  2) show that bacampicillin appears more rapidly and renders higher peak concentrations than pivampicillin and, on a molar basis, than amoxycillin. However, statistically significant differences were observed only between ampicillin and the others.
The serum concentrations were as expected compared with previous studies with similar doses (7, 8, 13, 18, 24) , except that a study by Miki (19) showed somewhat lower levels of amoxycillin. Considering that 70 to 80% of randomly selected Escherichia coli strains have minimum inhibitory concentrations below 5 ,ug of ampicillin per ml (23) , it is notable that the individual peak serum levels were above this level in all the subjects after bacampicillin and in all but one after pivampicillin. For amoxycillin, on the other hand, the peak serum levels were below this level in three subjects. Similarly, only in three volunteers were serum levels of 5 ,tg/ml briefly reached after the ampicillin tablets. Also, when the uniformity of the individual peak concentrations for each drug is compared ( (16, 17) , 82 to 89% with pivampicillin (16) , and 74 to 89% with amoxycillin (2, 33) .
The amounts recovered in the urine also reflect the bioavailability of each drug. Again, ampicillin was at the bottom with an 8-h excretion of 44.6 ± 14.8% (mean + standard deviation) of the dose as active ampicillin. The elimination had leveled off at this time. The three other compounds gave numbers of the same order ranging from 64.7 + 19.1% for pivampicillin to 73.5 ± 9.4% for amoxycillin. Amoxycillin had the highest mean value, while bacampicillin and pivampicillin had changed ranking order compared with the values of the area under the serum concentration-time curves. Precautions were taken so that breakdown of the antibiotic during collection was small, but, due to the considerable instability of the 84-lactam ring, one may view the serum data with more confidence. Furthermore, Cole et al. (6) and Miki (19) have shown that the portion excreted in the urine as antibacterially inactive ampicillin or amoxycillin penicilloate is in the order of 4 to 11 and 8 to 25%, respectively.
The relative bioavailability calculated from urinary recovery and area under the serum concentration-time curves showed good agreement.
The course of the serum curve reflects both the absorption rate constant (k,), and the elimination rate constant (k2). The k2 is somewhat higher and consequently t42 somewhat lower after bacampicillin than after the other compounds, implying that a prolonged absorption might have caused underestimates of the calculated k2 values for the other drugs. The better characteristics of bacampicillin are largely explained by the high degree and rate of absorption. Since the elimination rate is approximately equal for the four drugs, the differences in absorption rate explain why bacampicillin has favorable characteristics, i.e., the rapid appearance of ampicillin in serum and the high peaks.
Experimental studies indicate that the antibiotic concentration in the tissue is proportional to the peak serum level attained (1, 30) . High concentrations of antibiotics in the blood might render better diffusion into tissues because of the greater concentration gradient.
Furthermore, a correlation has been found between antimicrobial peak activity in serum and clinical outcome (14) . Thus, one may conclude that the high and more-uniform peak serum levels attained with bacampicillin are of potential clinical importance.
Consequently, bacampicillin represents a favorable development in ampicillin therapy from a pharmacokinetic point of view.
